Kathrin Nachtkamp
Overview
Explore the profile of Kathrin Nachtkamp including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
720
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jager P, Biermann B, Liebers N, Schulz F, Baermann B, Twarock S, et al.
EJHaem
. 2025 Mar;
6(2):e70012.
PMID: 40041662
Background: Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a key treatment for hematologic malignancies, but donor selection impacts outcomes. Results: In a cohort of 152 patients undergoing allo-SCT from 2012...
2.
Schulz F, Roggenbuck C, Kundgen A, Kasprzak A, Nachtkamp K, Jager P, et al.
Ann Hematol
. 2025 Jan;
104(1):231-239.
PMID: 39794531
As median age of patients with acute myeloid leukemia is 72 years, older patients continue to be a vulnerable cohort representing significant challenges in clinical practice. Patient-specific comorbidities as well...
3.
Kobbe G, Bruggemann M, Baermann B, Wiegand L, Trautmann H, Yousefian S, et al.
N Engl J Med
. 2024 Nov;
391(13):1217-1226.
PMID: 39589371
The development of a fatal, clonal, autonomously proliferating CD4-CD8- chimeric antigen receptor (CAR)+ peripheral T-cell lymphoma (PTCL) occurred 1 month after a patient received treatment with tisagenlecleucel for relapsed primary...
4.
Nachtkamp K, Strupp C, Faoro R, Gattermann N, Dietrich S, Germing U, et al.
Front Oncol
. 2024 Apr;
14:1359115.
PMID: 38665949
Gold standard for the establishment of the diagnosis of myelodysplastic syndromes (MDS) are cytomorphological features of hematopoietic cells in peripheral blood and bone marrow aspirates. There is increasing evidence that...
5.
Burmeister T, Stroh A, Kehden B, Trautmann H, Meyer C, Marschalek R, et al.
Leukemia
. 2024 Mar;
38(7):1600-1603.
PMID: 38519799
No abstract available.
6.
Kasprzak A, Andresen J, Nachtkamp K, Kundgen A, Schulz F, Strupp C, et al.
Cancers (Basel)
. 2024 Feb;
16(4).
PMID: 38398198
Despite notable advancements in infection prevention and treatment, individuals with hematologic malignancies still face the persistent threat of frequent and life-threatening complications. Those undergoing chemotherapy or other disease-modifying therapies are...
7.
Schulz F, Jager P, Tischer J, Fraccaroli A, Bug G, Hausmann A, et al.
Cancers (Basel)
. 2024 Feb;
16(3).
PMID: 38339283
Up to 50% of patients with high-risk myeloid malignancies die of relapse after allogeneic stem cell transplantation. Current sequential conditioning regimens like the FLAMSA protocol combine intensive induction therapy with...
8.
Schulz F, Nachtkamp K, Oster H, Mittelman M, Gattermann N, Schweier S, et al.
Int J Lab Hematol
. 2024 Jan;
46(3):510-514.
PMID: 38284270
Introduction: A previously published web-based App using Gradient-boosted models (GBMs) of eight laboratory parameters was established by Oster et al. to facilitate diagnosis or exclusion of myelodysplastic syndromes (MDS) in...
9.
10.
Silzle T, Blum S, Kasprzak A, Nachtkamp K, Rudelius M, Hildebrandt B, et al.
Cancers (Basel)
. 2023 Jul;
15(14).
PMID: 37509235
The absolute monocyte count (AMC) is associated with mortality in a variety of medical conditions. Its prognostic impact in myelodysplastic syndromes (MDSs) is less well studied. Therefore, we investigated its...